• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

在与多发性硬化症相关的HLA - DR15单倍型背景下T细胞对髓鞘碱性蛋白的反应:T细胞的肽结合、免疫显性及效应功能

T cell response to myelin basic protein in the context of the multiple sclerosis-associated HLA-DR15 haplotype: peptide binding, immunodominance and effector functions of T cells.

作者信息

Vergelli M, Kalbus M, Rojo S C, Hemmer B, Kalbacher H, Tranquill L, Beck H, McFarland H F, De Mars R, Long E O, Martin R

机构信息

Neuroimmunology Branch, NINDS, NIH, Bethesda, MD 20892-1400, USA.

出版信息

J Neuroimmunol. 1997 Aug;77(2):195-203. doi: 10.1016/s0165-5728(97)00075-1.

DOI:10.1016/s0165-5728(97)00075-1
PMID:9258250
Abstract

In this study, we evaluated the role of the two functional HLA-DR heterodimers, DR2a (DR alpha paired with the beta chain encoded by DRB50101) and DR2b (DR alpha paired with the beta chain encoded by DRB11501), that are coexpressed in the multiple sclerosis (MS)-associated haplotype HLA-DR15 Dw2, in presenting myelin basic protein (MBP) peptides to MBP-specific T cell lines (TCL). Our results show that both HLA-DR molecules serve as restriction elements for HLA-DR15-restricted TCL. Slightly higher numbers of TCL use DR2a as restriction element, and the epitopes contained in the immunodominant C-terminal region (131-159) are uniquely restricted by DR2a. The immunodominant middle epitope (81-99) is recognized in the context of both DR2a and DR2b, but this specificity strongly dominates the DR2b-restricted T cell response. Overall, immunodominance in the MBP-specific T cell response correlated well with peptide binding to DR2a or DR2b, demonstrating that the affinity of MHC-peptide interactions is important for shaping the T cell response to this autoantigen. Furthermore, we show that binding of the middle MBP peptide to HLA-DR15 molecules prevents cleavage by cathepsin D, a protease abundantly found in endosomal processing compartments, and thus contributes to its immunodominance. Surprisingly, the restriction element employed by MBP-specific T cell clones influenced the effector function (i.e., cytotoxic activity) of T cells irrespective of their peptide fine specificity.

摘要

在本研究中,我们评估了两种功能性HLA-DR异二聚体DR2a(DRα与由DRB50101编码的β链配对)和DR2b(DRα与由DRB11501编码的β链配对)的作用,它们在与多发性硬化症(MS)相关的单倍型HLA-DR15 Dw2中共表达,负责将髓鞘碱性蛋白(MBP)肽呈递给MBP特异性T细胞系(TCL)。我们的结果表明,这两种HLA-DR分子均作为HLA-DR15限制性TCL的限制元件。使用DR2a作为限制元件的TCL数量略多,并且免疫显性C末端区域(131-159)中包含的表位仅由DR2a限制。免疫显性中间表位(81-99)在DR2a和DR2b的背景下均被识别,但这种特异性在DR2b限制性T细胞应答中占主导地位。总体而言,MBP特异性T细胞应答中的免疫显性与肽与DR2a或DR2b的结合密切相关,表明MHC-肽相互作用的亲和力对于塑造针对该自身抗原的T细胞应答很重要。此外,我们表明中间MBP肽与HLA-DR15分子的结合可防止组织蛋白酶D(一种在内体加工区室中大量存在的蛋白酶)的切割,从而有助于其免疫显性。令人惊讶的是,MBP特异性T细胞克隆所采用的限制元件影响了T细胞的效应功能(即细胞毒性活性),而与它们的肽精细特异性无关。

相似文献

1
T cell response to myelin basic protein in the context of the multiple sclerosis-associated HLA-DR15 haplotype: peptide binding, immunodominance and effector functions of T cells.在与多发性硬化症相关的HLA - DR15单倍型背景下T细胞对髓鞘碱性蛋白的反应:T细胞的肽结合、免疫显性及效应功能
J Neuroimmunol. 1997 Aug;77(2):195-203. doi: 10.1016/s0165-5728(97)00075-1.
2
Structural basis for the binding of an immunodominant peptide from myelin basic protein in different registers by two HLA-DR2 proteins.两种HLA - DR2蛋白以不同配列结合髓鞘碱性蛋白中一种免疫显性肽的结构基础。
J Mol Biol. 2000 Nov 24;304(2):177-88. doi: 10.1006/jmbi.2000.4198.
3
Immunodominance of a low-affinity major histocompatibility complex-binding myelin basic protein epitope (residues 111-129) in HLA-DR4 (B1*0401) subjects is associated with a restricted T cell receptor repertoire.在HLA - DR4(B1*0401)受试者中,低亲和力的主要组织相容性复合体结合髓鞘碱性蛋白表位(第111 - 129位氨基酸残基)的免疫显性与受限的T细胞受体库相关。
J Clin Invest. 1997 Jul 15;100(2):339-49. doi: 10.1172/JCI119539.
4
HLA-DR2a is the dominant restriction molecule for the cytotoxic T cell response to myelin basic protein in DR2Dw2 individuals.HLA - DR2a是DR2Dw2个体中细胞毒性T细胞对髓鞘碱性蛋白反应的主要限制性分子。
J Immunol. 1990 Nov 1;145(9):2880-5.
5
Myelin autoreactivity in multiple sclerosis: recognition of myelin basic protein in the context of HLA-DR2 products by T lymphocytes of multiple-sclerosis patients and healthy donors.多发性硬化症中的髓鞘自身反应性:多发性硬化症患者和健康供体的T淋巴细胞在HLA - DR2产物背景下对髓鞘碱性蛋白的识别。
Proc Natl Acad Sci U S A. 1990 Oct;87(20):7968-72. doi: 10.1073/pnas.87.20.7968.
6
Structural requirements for binding of an immunodominant myelin basic protein peptide to DR2 isotypes and for its recognition by human T cell clones.免疫显性髓鞘碱性蛋白肽与DR2同种型结合及其被人T细胞克隆识别的结构要求。
J Exp Med. 1994 Jan 1;179(1):279-90. doi: 10.1084/jem.179.1.279.
7
Visualization of myelin basic protein (MBP) T cell epitopes in multiple sclerosis lesions using a monoclonal antibody specific for the human histocompatibility leukocyte antigen (HLA)-DR2-MBP 85-99 complex.使用针对人类组织相容性白细胞抗原(HLA)-DR2-MBP 85-99复合物的单克隆抗体,对多发性硬化症病变中的髓鞘碱性蛋白(MBP)T细胞表位进行可视化。
J Exp Med. 2000 Apr 17;191(8):1395-412. doi: 10.1084/jem.191.8.1395.
8
Design, engineering, and production of human recombinant t cell receptor ligands derived from human leukocyte antigen DR2.源自人类白细胞抗原DR2的人重组T细胞受体配体的设计、工程和生产。
J Biol Chem. 2001 Jun 29;276(26):24170-6. doi: 10.1074/jbc.M101808200. Epub 2001 Apr 23.
9
Myelin basic protein-specific T lymphocyte repertoire in multiple sclerosis. Complexity of the response and dominance of nested epitopes due to recruitment of multiple T cell clones.多发性硬化症中髓鞘碱性蛋白特异性T淋巴细胞库。由于多个T细胞克隆的募集导致反应的复杂性和嵌套表位的优势。
J Clin Invest. 1993 Dec;92(6):2633-43. doi: 10.1172/JCI116879.
10
Fine specificity and HLA restriction of myelin basic protein-specific cytotoxic T cell lines from multiple sclerosis patients and healthy individuals.来自多发性硬化症患者和健康个体的髓鞘碱性蛋白特异性细胞毒性T细胞系的精细特异性和HLA限制
J Immunol. 1990 Jul 15;145(2):540-8.

引用本文的文献

1
Mimicking the brain: Epstein-Barr virus and foreign agents as drivers of neuroimmune attack in multiple sclerosis.模拟大脑:EB 病毒和外来因子作为多发性硬化症神经免疫攻击的驱动因素。
Front Immunol. 2023 Nov 3;14:1304281. doi: 10.3389/fimmu.2023.1304281. eCollection 2023.
2
Risk HLA Variants Affect the T-Cell Repertoire in Multiple Sclerosis.风险 HLA 变体影响多发性硬化症中的 T 细胞库。
Neurol Neuroimmunol Neuroinflamm. 2023 Feb 15;10(3). doi: 10.1212/NXI.0000000000200093. Print 2023 May.
3
HLA Class II Genotype Does Not Affect the Myelin Responsiveness of Multiple Sclerosis Patients.
人类白细胞抗原II类基因型不影响多发性硬化症患者的髓鞘反应性。
Cells. 2020 Dec 17;9(12):2703. doi: 10.3390/cells9122703.
4
DRB4*01:01 Has a Distinct Motif and Presents a Proinsulin Epitope That Is Recognized in Subjects with Type 1 Diabetes.DRB4*01:01 具有独特的基序,并呈现出在 1 型糖尿病患者中被识别的胰岛素原表位。
J Immunol. 2018 Dec 15;201(12):3524-3533. doi: 10.4049/jimmunol.1800723. Epub 2018 Nov 19.
5
Structure-based selection of human metabolite binding P4 pocket of DRB1*15:01 and DRB1*15:03, with implications for multiple sclerosis.基于结构的人类代谢物结合物对 DRB1*15:01 和 DRB1*15:03 的 P4 口袋的选择,对多发性硬化症有影响。
Genes Immun. 2019 Jan;20(1):46-55. doi: 10.1038/s41435-017-0009-5. Epub 2018 Jan 20.
6
Antigen Presentation, Autoantigens, and Immune Regulation in Multiple Sclerosis and Other Autoimmune Diseases.多发性硬化症及其他自身免疫性疾病中的抗原呈递、自身抗原与免疫调节
Front Immunol. 2015 Jun 17;6:322. doi: 10.3389/fimmu.2015.00322. eCollection 2015.
7
Small molecule inhibitor of antigen binding and presentation by HLA-DR2b as a therapeutic strategy for the treatment of multiple sclerosis.HLA-DR2b 抗原结合和呈递的小分子抑制剂作为多发性硬化症治疗策略。
J Immunol. 2013 Nov 15;191(10):5074-84. doi: 10.4049/jimmunol.1300407. Epub 2013 Oct 11.
8
Myelin basic protein-specific TCR/HLA-DRB5*01:01 transgenic mice support the etiologic role of DRB5*01:01 in multiple sclerosis.髓鞘碱性蛋白特异性 TCR/HLA-DRB5*01:01 转基因小鼠支持 DRB5*01:01 在多发性硬化中的病因作用。
J Immunol. 2012 Sep 15;189(6):2897-908. doi: 10.4049/jimmunol.1103087. Epub 2012 Aug 10.
9
Immune tolerance in multiple sclerosis.多发性硬化症的免疫耐受。
Immunol Rev. 2011 May;241(1):228-40. doi: 10.1111/j.1600-065X.2011.01016.x.
10
An automated framework for understanding structural variations in the binding grooves of MHC class II molecules.一种用于理解 MHC Ⅱ类分子结合槽结构变异的自动化框架。
BMC Bioinformatics. 2010 Jan 18;11 Suppl 1(Suppl 1):S55. doi: 10.1186/1471-2105-11-S1-S55.